EFFECT OF ECLIPTA ALBA ON SCOPOLAMINE INDUCED AMNESIA IN MICE
The present study deals with the evaluation of potential effects of Eclipta alba (EA) in memory impairment of mice. Memory impairment was induced by scopolamine (3 mg/kg, i.p) in animals. To assess learning and memory in mice Morris water maze test was employed. The acetylcholinestrase enzyme (AChE) activity in brain was measured to evaluate the central cholinergic activity. The levels of thiobarbituric acid-reactive species (TBARS) and reduced glutathione (GSH)in brain were estimated to assess the degree of oxidative stress. Scopolamine treatment produces significant impairment of learning and memory in mice, as reflected by a significant decrease in MWM performance. Scopolamine also produced a significant enhancement of brain AChE activity and brain oxidative stress (increase in TBARS and decrease in GSH) levels. EA (300 and 600 mg/kg,oral) significantly prevented scopolamine-induced learning and memory deficits along with decrease of scopolamine-induced rise in brain AChE activity and brain oxidative stress levels. It may be concluded that Eclipta alba has significant protective action against scopolamine induced memory deficits in mice that can be attributed to its anti AChE and anti oxidant actions.
Keywords: Alzheimer disease, Oxidative stress, Morris water Maze, Scopolamine
2. Balmiki R, Debomoy K. Neuroinflammation in Alzheimer’s disease: different molecular targets and potential therapeutic agents including curcumin. Current Opinion in Pharmacology.2009; 9:434–444.
3. Peter J, Melanie J. Natural products and derivatives affecting neurotransmission relevant to Alzheimers and parkinsons disease.Neurosignala.2007; 14:6-22.
4. Hebert L, Scher P, Bienias J. Alzheimer’s disease in US population: prevalence estimates using the 2000 census. Arch. Neurol.2003; 60: 1119-1122.
5. Vinutha B, Prashanth D, Salma K, Sreeja S, Pratiti D, Padmaja R, Radhika S, Amit A, Venkateshwarlu K, Deepak M.Screening of selected Indian medicinal plants for acetylcholinesterase inhibitory activity. Journal of Ethnopharmacololgy. 2007; 109: 359–363.
6. Frank B, Gupta S.A review of antioxidants and Alzheimers disease. Ann clin Psych.2005; 17:269-286.
7. Kennedy D, Scholey A. The psychopharmacology of Europian herbs with cognition-enhancing properties.Curr Pharm Des.2006; 12:4613-4623.
8. Zhang ZJ. Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Science.2004; 75:1659–99.
9. Gilgun-Sherki Y, Melamed E, Offen D. Antioxidant treatment in Alzheimer’s disease: Current state. Journal of Mol Neuroscience. 2002; 21:1–11.
10. Uniyal R, Sandhu S, Chandok J.Herbology. In:The Ayurvedic Encyclopedia. Sri Satguru Publications, India, 1998: 77.
11. Satyavati G, Rana M, Sharma M. In: Medicinal Plants of India. Cambridge Printing Works.1976; I: 370–372.
12. Vaidya A. The status and scope of Indian medicinal plants acting on central nervous system. Indian Journal of Pharmacology. 1997; 29: 340–343.
13. Zafar R, Sagar B. In vitro plant regeneration of Eclipta alba and increased production of coumestans. Fitoterapia.1999; 70:348-356.
14. Upadhyay R, Pandey M, Jha R, Pandey V. Eclalbatin,a triterpine saponins from Eclipta alba. Journal Asian Natural Products and Research.2001; 3:213–217.
15. Wagner H, Geyer B, Kiso Y, Hikino H, Rao GS. Coumestans as main active principles of the liver drugs Eclipta alba and Wedelia calendulaceae. Planta Medica.1986; 5: 370–373.
16. Saxena A, Singh B, Anand K. Hepatoprotective effects of Eclipta alba on sub cellular levels in rats. Journal of Ethnopharmacol, 1993; 40: 155–161.
17. Singh B, Saxena A, Chandan B, Agarwal S, Anand K.In vivo hepatoprotective activity of active fraction from ethanolic extract of Eclipta alba leaves. Indian Journal of Physiology and Pharmacology.2001; 45:435–441.
18. Beatty WW, Butters N, Janowsky DS. Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behavioral and Neural Biology.1986; 45:196–211.
19. Kopelman MD, Corn TH. Cholinergic ‘blockade’ as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. Brain.1988; 111:1079–110.
20. Fan Y, Hu J, Li J. Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms. Neurosci Lett.2005; 374:222–6.
21. Jeong EJ, Lee KY, Kim SH. Cognitive-enhancing and antioxidant activities of iridoid glycosides from Scrophularia buergeriana in scopolamine treated mice. European Journal of Pharmacology. 2008; 588:78–84.
22. El-Sherbiny DA, Khalifa AE, Attia AS, Eldenshary EES. Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnesic dose of scopolamine. Pharmacology Biochemistry Behaviour.2003; 76:523–33.
23. Parle M, Singh N. Animal models of testing memory. Asia Pacific Journal of Pharmacology.2004; 16:101-20.
24. Ellman GL. A New and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology 1961; 7: 88-95.
25. Voss G, Sachsse K. Red cell and plasma cholinesterase activities in microsamples of human and animal blood determined simultaneously by a modified acetylthiocholine-DTNB procedure. Toxicol Appl Pharmacol 1970; 16(3):764-72.
26. Ohkawa H. Assay for lipid peroxides in animal tissues by Thiobarbituric acid reaction. Anayticall Biochemistry. 1979; 95(2):351-8.
27. Beutler E, Duron O, Kelly B. Reduced glutathione estimation.j Lb clinical med. 1963; 61:82.
28. Sharma B, Singh N, Singh M. Modulation of celecoxib and Streptozotocin induced experimental dementia of Alzheimer’s disease type by pitavastatin and donepezil. Journal of Psychopharmacology 2008; 22:162-71.
29. Whitehouse PJ, Price DL, Struble RG. Alzheimer’s disease and senile dementia: Loss of neurons in the basal forebrain. Science.1982; 215:1237–39.
30. Drachman DA, Leavitt J. Human memory and the cholinergic system: A relationship to aging? Arch Neurol.1974; 30:113–21.
31. Sunderland T, Tariot PN, Cohen RM. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age matched controls: A dose-response study. Arch Gen Psychiatry. 1987; 44:418–26.
32. Pahaye DB, Bum EN, Taiwe GS, Ngoupaye GT, Sidiki N, Moto FCO, Kouemou N, Njapdounke SJK, Nkantchoua G, Kandeda A, Omam JPO, Mairaira, Ojong JL.Neuroprotective and Antiamnesic Effects of Mitragynainermis Willd (Rubiaceae) on Scopolamine-Induced Memory Impairment in Mice. Behavioural Neurology. 2017; 5952897:11.
33. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer’s disease brain: Central role of amyloid β-peptide. Trends in Molecular Medicine. 2001; 7:548–554.
34. Marcus DL, Thomas C, Rodriquez C. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer’s disease. Experimental Neurology. 1998; 150:40–4.
35. Dringen R. Glutathione metabolism and oxidative stress in neuro-degeneration. European Journal of Biochemistry.2000; 267:4903.
36. Citron M. Alzheimer’s disease: Strategies for disease modification.Nat Rev Drug Discov. 2010; 9:387–98.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).